These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18047674)

  • 41. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Jørgensen HG; Holyoake TL
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro.
    Finn RS; Aleshin A; Dering J; Yang P; Ginther C; Desai A; Zhao D; von Euw E; Busuttil RW; Slamon DJ
    Hepatology; 2013 May; 57(5):1838-46. PubMed ID: 23299860
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling.
    Levitt JM; Yamashita H; Jian W; Lerner SP; Sonpavde G
    Mol Cancer Ther; 2010 May; 9(5):1128-35. PubMed ID: 20406945
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.
    Oweini H; Otrock ZK; Mahfouz RA; Bazarbachi A
    Arch Gynecol Obstet; 2011 Jan; 283(1):133-4. PubMed ID: 20473616
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
    Hochhaus A; Baccarani M; Deininger M; Apperley JF; Lipton JH; Goldberg SL; Corm S; Shah NP; Cervantes F; Silver RT; Niederwieser D; Stone RM; Dombret H; Larson RA; Roy L; Hughes T; Müller MC; Ezzeddine R; Countouriotis AM; Kantarjian HM
    Leukemia; 2008 Jun; 22(6):1200-6. PubMed ID: 18401416
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Src as a therapeutic target in men with prostate cancer and bone metastases.
    Saad F
    BJU Int; 2009 Feb; 103(4):434-40. PubMed ID: 19154462
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Practical management of dasatinib for maximum patient benefit.
    Galinsky I; Buchanan S
    Clin J Oncol Nurs; 2009 Jun; 13(3):329-35. PubMed ID: 19502192
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dasatinib: is it all in the dose?
    Condorelli F; Genazzani AA
    BioDrugs; 2010 Jun; 24(3):157-63. PubMed ID: 20222756
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic and therapeutic value of the Eph/Ephrin signaling pathway in pancreatic cancer explored based on bioinformatics.
    Liu J; Yuan Q; Chen X; Yang Y; Xie T; Zhang Y; Qi B; Li S; Shang D
    Sci Rep; 2024 Jul; 14(1):17650. PubMed ID: 39085301
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Computational identification of natural senotherapeutic compounds that mimic dasatinib based on gene expression data.
    Meiners F; Hinz B; Boeckmann L; Secci R; Sueto S; Kuepfer L; Fuellen G; Barrantes I
    Sci Rep; 2024 Mar; 14(1):6286. PubMed ID: 38491064
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of changes in expression of
    Krushkal J; Zhao Y; Roney K; Zhu W; Brooks A; Wilsker D; Parchment RE; McShane LM; Doroshow JH
    Epigenetics; 2024 Dec; 19(1):2309824. PubMed ID: 38369747
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel [
    Furukawa T; Kimura H; Sasaki M; Yamada T; Iwasawa T; Yagi Y; Kato K; Yasui H
    ACS Omega; 2023 Feb; 8(7):7030-7035. PubMed ID: 36844571
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of candidate hub genes correlated with the pathogenesis, diagnosis, and prognosis of prostate cancer by integrated bioinformatics analysis.
    Wei T; Liang Y; Anderson C; Zhang M; Zhu N; Xie J
    Transl Cancer Res; 2022 Oct; 11(10):3548-3571. PubMed ID: 36388030
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FOXA1 in prostate cancer.
    Dong HY; Ding L; Zhou TR; Yan T; Li J; Liang C
    Asian J Androl; 2023; 25(3):287-295. PubMed ID: 36018068
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity.
    Mazzu YZ; Liao Y; Nandakumar S; Sjöström M; Jehane LE; Ghale R; Govindarajan B; Gerke TA; Lee GM; Luo JH; Chinni SR; Mucci LA; Feng FY; Kantoff PW
    Mol Oncol; 2022 Jul; 16(13):2451-2469. PubMed ID: 34792282
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Putative Single-Photon Emission CT Imaging Tracer for Erythropoietin-Producing Hepatocellular A2 Receptor.
    Furukawa T; Kimura H; Torimoto H; Yagi Y; Kawashima H; Arimitsu K; Yasui H
    ACS Med Chem Lett; 2021 Aug; 12(8):1238-1244. PubMed ID: 34413953
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting EphA2 in cancer.
    Xiao T; Xiao Y; Wang W; Tang YY; Xiao Z; Su M
    J Hematol Oncol; 2020 Aug; 13(1):114. PubMed ID: 32811512
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting SRC Family Kinases in Mesothelioma: Time to Upgrade.
    Indovina P; Forte IM; Pentimalli F; Giordano A
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32664483
    [No Abstract]   [Full Text] [Related]  

  • 60. Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned so Far.
    Martellucci S; Clementi L; Sabetta S; Mattei V; Botta L; Angelucci A
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32498343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.